MGCD265

DRUG4 trials

Sponsors

Mirati Therapeutics Inc.

Conditions

Advanced CancerAdvanced MalignanciesNon-Small Cell Lung Cancer

Phase 1

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

CompletedNCT00679133

Mirati Therapeutics Inc.Advanced Malignancies

Start: 2008-04-30End: 2011-03-31Updated: 2015-01-08

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

CompletedNCT00697632

Mirati Therapeutics Inc.Advanced Cancer

Start: 2008-06-30End: 2019-01-31Updated: 2019-02-12

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

CompletedNCT01930006

Mirati Therapeutics Inc.Advanced Malignancies

Start: 2013-08-31End: 2013-12-31Updated: 2015-01-08

Phase 2

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

CompletedNCT02544633

Mirati Therapeutics Inc.Non-Small Cell Lung Cancer

Start: 2015-10-31End: 2019-01-31Updated: 2020-03-04

Related Papers

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.

2022-12-0215 citations

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (<i>MET</i>).

Journal of Clinical Oncology2016-05-206 citations

Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2016-05-20

Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2015-05-2013 citations